BRPI0820673A2 - Formulações e composições farmacêuticas de fenilefrina para absorção transmucosal - Google Patents

Formulações e composições farmacêuticas de fenilefrina para absorção transmucosal

Info

Publication number
BRPI0820673A2
BRPI0820673A2 BRPI0820673-2A BRPI0820673A BRPI0820673A2 BR PI0820673 A2 BRPI0820673 A2 BR PI0820673A2 BR PI0820673 A BRPI0820673 A BR PI0820673A BR PI0820673 A2 BRPI0820673 A2 BR PI0820673A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
transmucosal absorption
phenylephrine
formulations
phenylephrine formulations
Prior art date
Application number
BRPI0820673-2A
Other languages
English (en)
Inventor
John O'mullane
Dennis Nelson
Xiaoming Chen
David Monteith
Joseph P Reo
Jiansheng Wan
Mohammed A Kabir
Original Assignee
Schering Plough Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40510498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0820673(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Plough Healthcare filed Critical Schering Plough Healthcare
Publication of BRPI0820673A2 publication Critical patent/BRPI0820673A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0820673-2A 2007-12-07 2008-12-04 Formulações e composições farmacêuticas de fenilefrina para absorção transmucosal BRPI0820673A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1222307P 2007-12-07 2007-12-07
PCT/US2008/085523 WO2009076165A1 (en) 2007-12-07 2008-12-04 Phenylephrine pharmaceutical formulations and compositions for transmucosal absorption

Publications (1)

Publication Number Publication Date
BRPI0820673A2 true BRPI0820673A2 (pt) 2015-06-16

Family

ID=40510498

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820673-2A BRPI0820673A2 (pt) 2007-12-07 2008-12-04 Formulações e composições farmacêuticas de fenilefrina para absorção transmucosal

Country Status (17)

Country Link
US (1) US20090280160A1 (pt)
EP (1) EP2237767A1 (pt)
JP (1) JP2011506337A (pt)
KR (1) KR20100102632A (pt)
CN (1) CN101938991A (pt)
AR (1) AR069572A1 (pt)
AU (1) AU2008335464A1 (pt)
BR (1) BRPI0820673A2 (pt)
CA (1) CA2709208A1 (pt)
CL (1) CL2008003615A1 (pt)
CO (1) CO6321221A2 (pt)
MX (1) MX2010006284A (pt)
PE (1) PE20091084A1 (pt)
RU (1) RU2010127737A (pt)
TW (1) TW200932208A (pt)
WO (1) WO2009076165A1 (pt)
ZA (1) ZA201004654B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2956120B1 (en) * 2013-02-13 2020-04-15 The Procter and Gamble Company Anise flavored medication
US20190008759A1 (en) * 2014-07-03 2019-01-10 Darren Rubin Safer and more effective methods of transmucosal delivery for raising blood pressure and stimulating the body
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
WO2017192921A1 (en) * 2016-05-05 2017-11-09 Monosol Rx, Llc Enhanced delivery epinephrine compositions
MX2019007923A (es) 2016-12-31 2019-09-10 Bioxcel Therapeutics Inc Uso de dexmedetomidina sublingual para el tratamiento de la agitacion.
RU2751193C2 (ru) 2017-01-11 2021-07-12 Ферринг Б.В. Быстро распадающаяся фармацевтическая композиция
WO2019021476A1 (ja) * 2017-07-28 2019-01-31 社会医療法人蘇西厚生会 まつなみリサーチパーク アレルギー症状の予防又は治療剤
KR20200060748A (ko) * 2017-09-27 2020-06-01 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 및 프로드러그 조성물
US10792246B2 (en) 2018-06-27 2020-10-06 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US20240024288A1 (en) 2019-07-19 2024-01-25 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2021247647A1 (en) * 2020-06-02 2021-12-09 Mohamed Hussein Hamdan Sublingual formulation for hypotension and syncope
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558768A (en) * 1969-12-19 1971-01-26 Sterling Drug Inc Sustained release pharmaceutical compositions
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4427681A (en) * 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
US5025019A (en) * 1984-04-09 1991-06-18 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4623664A (en) * 1985-10-31 1986-11-18 University Of Iowa Research Foundation Oil suspended phenylephrine
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
JPH0794379B2 (ja) * 1990-08-07 1995-10-11 ファイザー・インコーポレーテッド 放出製剤における界面重合膜の使用方法
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
GB9422571D0 (en) * 1994-11-09 1995-01-04 Whitehall Lab Ltd Haemorrihoidal compositions and method of use
US5827531A (en) * 1994-12-02 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microcapsules and methods for making
NL1005394C1 (nl) * 1996-04-01 1997-10-02 Kokbing Lo Bevestigingselement en band bevestigd met bevestigingselement.
CA2275663C (en) * 1996-12-23 2008-03-18 Robin Kenneth Stewart Phillips Pharmaceutical compositions comprising .alpha.-adrenergic agonists for the treatment of fecal incontinence
AU750809B2 (en) * 1997-09-26 2002-07-25 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US6521254B2 (en) * 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6267986B1 (en) * 1999-09-24 2001-07-31 Ranbaxy Laboratories Limited Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
AU2276801A (en) * 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
WO2001089476A1 (en) * 2000-05-19 2001-11-29 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
WO2003009834A1 (en) * 2000-08-17 2003-02-06 Battey Alyce S Oral delivery of pharmaceuticals via encapsulation
US20030236275A1 (en) * 2002-06-20 2003-12-25 Schering Corporation Treatment methods of nasal congestion and nasal obstruction
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
WO2003019948A1 (en) * 2001-08-27 2003-03-06 Koninklijke Philips Electronics N.V. Video data processor
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US20030083354A1 (en) * 2001-10-26 2003-05-01 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
US20030114535A1 (en) * 2001-12-14 2003-06-19 Jame Fine Chemicals, Inc. Dextrochlorpheniramine tannate
US20040122107A1 (en) * 2002-09-13 2004-06-24 Fine Jeffrey R Method of alleviating barometric-induced symptoms in airline passengers
JP2004121962A (ja) * 2002-10-01 2004-04-22 National Institute Of Advanced Industrial & Technology ナノバブルの利用方法及び装置
US6979689B2 (en) * 2002-12-20 2005-12-27 Pediamed Pharmaceuticals, Inc. Compositions and methods for treating upper respiratory congestion
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20070219253A1 (en) * 2003-09-17 2007-09-20 Gul Balwani Decongestant / antihistaminic / expectorant compositions
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
JP2007517806A (ja) * 2004-01-15 2007-07-05 オーラル バイオサイエンス ピーティーワイ． リミテッド 口腔用麻酔ゲル
BRPI0518553A2 (pt) * 2004-12-13 2008-11-25 Mcneil Ppc Inc composiÇço farmacÊutica estÁvel, mÉtodo para estabilizaÇço de pelo menos um ingrediente farmaceuticamente ativo e mÉtodo de uso de celulose microcristalina silicificada
US8318210B2 (en) * 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
AU2005333081B2 (en) * 2005-06-17 2010-06-24 Aft Pharmaceuticals Limited Novel pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
US8940796B2 (en) * 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US9005652B2 (en) * 2006-07-25 2015-04-14 Wyeth Chewable tablet containing phenylephrine
US7378082B1 (en) * 2007-11-05 2008-05-27 Inspire Pharmaceuticals, Inc. Method for treating allergic rhinitis without adverse effects

Also Published As

Publication number Publication date
MX2010006284A (es) 2010-09-07
CN101938991A (zh) 2011-01-05
PE20091084A1 (es) 2009-07-23
ZA201004654B (en) 2011-03-30
KR20100102632A (ko) 2010-09-24
AU2008335464A1 (en) 2009-06-18
WO2009076165A1 (en) 2009-06-18
CL2008003615A1 (es) 2009-10-16
TW200932208A (en) 2009-08-01
CO6321221A2 (es) 2011-09-20
US20090280160A1 (en) 2009-11-12
CA2709208A1 (en) 2009-06-18
AR069572A1 (es) 2010-02-03
RU2010127737A (ru) 2012-01-20
EP2237767A1 (en) 2010-10-13
JP2011506337A (ja) 2011-03-03

Similar Documents

Publication Publication Date Title
BRPI0820673A2 (pt) Formulações e composições farmacêuticas de fenilefrina para absorção transmucosal
LTC2140867I2 (lt) Farmacinė kompozicija
LTPA2018014I1 (lt) Farmacinė kompozicija 514
BRPI0721651A2 (pt) Composição farmacêutica
BRPI0715712A2 (pt) Composição farmacêutica
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
BRPI0913379A2 (pt) formulações farmacêuticas sólidas compreendendo bibw 2992
BRPI0719393A2 (pt) Composição farmacêutica
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
DK1884242T3 (da) Farmaceutisk sammensætning omfattende lurasidon
BRPI0908596A2 (pt) formulação e composição farmacêutica de liberação prolongada
BRPI0919466A2 (pt) composição farmacêutica para liberação modificada
ATE493119T1 (de) Pharmazeutische zusammensetzung
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0720234A2 (pt) Composição farmacêutica
DK2285413T3 (da) Farmaceutisk sammensætning
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
BRPI0817833A2 (pt) Composição farmacêutica antimalárica
BRPI0921313A2 (pt) composição farmaucêutica
BRPI0820198A2 (pt) composições farmacêuticas
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
DE602008005137D1 (de) Chinolonverbindung und pharmazeutische zusammensetzung
BRPI0912171A2 (pt) composição farmacêutica
BRPI0812000A2 (pt) Métodos e composições para administração de oxibutinina

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MSD CONSUMER CARE, INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.